Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 2—February 2026
Research Letter
Acute Severe Hepatitis B Virus Infection in Previously Vaccinated Patient during Acalabrutinib Treatment
Table 1
Blood test results from a case of severe HBV infection in previously vaccinated patient during acalabrutinib treatment*
| Biochemical parameter | Before HBV infection | Day of hospitalization |
||||||
|---|---|---|---|---|---|---|---|---|
| −13 | −3 | 0 | 1 | 2 | 3 | 4 | ||
| Total bilirubin, mg/dL |
0.84 |
2.19 |
23.04 |
43.02 |
32.17 |
33.76 |
33.89 |
35.66 |
| Alanine aminotransferase, U/L |
27 |
NA |
2,688 |
3,780 |
2,603 |
2,024 |
1,340 |
875 |
| Aspartate aminotransferase, U/L |
29 |
945 |
3,877 |
4,400 |
3,146 |
2,384 |
1,058 |
NA |
| Alkaline phosphatase, U/L |
NA |
NA |
212 |
211 |
164 |
NA |
147 |
NA |
| Gamma-glutamyltransferase, U/L |
NA |
NA |
421 |
233 |
171 |
NA |
107 |
NA |
| Ammonia, µmol/L |
NA |
NA |
NA |
221 |
NA |
NA |
92 |
NA |
| International normalized ratio |
NA |
NA |
2.89 |
>6.12 |
>6.12 |
>6.12 |
>8.6 |
>8.6 |
| Creatinine, mg/dL |
0.79 |
0.66 |
0.69 |
1.63 |
2.33 |
3.13 |
3.94 |
4.43 |
| Sodium, mmol/L |
141 |
136 |
136 |
129 |
126 |
121 |
118 |
117 |
| Potassium, mmol/L |
4.3 |
4.5 |
4.5 |
6.4 |
5.9 |
5.1 |
4.6 |
4.6 |
| Hemoglobin, g/dL |
13.7 |
13.9 |
NA |
14.3 |
11.8 |
11.1 |
9.9 |
9.5 |
| Erythrocytes, × 1012 cells/L |
4.02 |
4.13 |
NA |
4.4 |
3.55 |
3.38 |
3.0 |
2.9 |
| Platelets, × 109/L |
207 |
150 |
NA |
245 |
159 |
135 |
89 |
80 |
| Total leukocytes, × 109 cells/L |
8.01 |
6.1 |
NA |
8.33 |
7.43 |
6.24 |
5.27 |
5.04 |
| C-reactive protein, mg/L |
1.12 |
NA |
21.17 |
14.85 |
9.38 |
NA |
4.08 |
NA |
| Procalcitonin, ng/mL | NA | NA | NA | NA | 0.84 | 0.81 | NA | 0.61 |
*HBV, hepatitis B virus; NA, not available.
Page created: January 29, 2026
Page updated: February 09, 2026
Page reviewed: February 09, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.